Results 51 to 60 of about 4,513 (159)

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

open access: yesCancer Management and Research, 2013
Samantha Humphreys,1 James Pellissier,2 Alison Jones3 1Market Access Department, Merck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, UK; 2Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA; 3Department of Medical Oncology ...
Humphreys S, Pellissier J, Jones A
doaj  

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 146-155, July 2025.
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang   +6 more
wiley   +1 more source

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

open access: yesDrug Design, Development and Therapy, 2020
Meng-Jie Yang, Hong-Rong Xu, Hui Li, Wei-Li Chen, Fei Yuan, Xue-Ning Li Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Xue-Ning LiDepartment of Clinical Pharmacology ...
Yang MJ   +5 more
doaj  

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

open access: yesSmall, Volume 21, Issue 29, July 24, 2025.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai   +5 more
wiley   +1 more source

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

open access: yesActa Dermato-Venereologica, 2019
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs.
Athanasios Tsianakas   +12 more
doaj   +1 more source

Gαq signalling from endosomes: A new conundrum

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 14, Page 3068-3089, July 2025.
Abstract G‐protein‐coupled receptors (GPCRs) constitute the largest family of membrane receptors, and are involved in the transmission of a variety of extracellular stimuli such as hormones, neurotransmitters, light and odorants into intracellular responses.
Carole Daly, Bianca Plouffe
wiley   +1 more source

Aprepitant [PDF]

open access: hybrid, 2020
National Cancer Institute
openalex   +1 more source

The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages

open access: yesDrug Design, Development and Therapy, 2020
Xiao-nan Zhao,* Zhen-zi Bai,* Cheng-hua Li, Chuan-lun Sheng, Hong-yan Li Department of Infectious, The Third Hospital of Jilin University, Changchun City, Jilin Province 130033, People’s Republic of China*These authors contributed equally to this ...
Zhao X, Bai Z, Li C, Sheng C, Li H
doaj  

Cytotoxic and apoptotic effects of neurokinin-1 receptor (NK1R) antagonist on multiple myeloma cells [PDF]

open access: yesمجله علمی دانشگاه علوم پزشکی کردستان, 2019
Background and Aim: Despite therapeutic improvements in recent decades, multiple myeloma (MM) still remains as one of the leading causes of death all over the world. Previous studies have indicated role of neurokinin-1 receptor (NK1R) in the pathogenesis
Elham Razani, Davood Bashash
doaj   +1 more source

Home - About - Disclaimer - Privacy